Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned an average rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $66.75.

Several research firms have weighed in on ARCT. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $16.41 on Friday. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00. The firm has a market capitalization of $444.55 million, a PE ratio of -7.39 and a beta of 2.63. The stock has a 50-day simple moving average of $17.38 and a two-hundred day simple moving average of $19.80.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter last year, the business posted ($0.61) earnings per share. Equities analysts forecast that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after buying an additional 712,650 shares during the period. ARK Investment Management LLC lifted its stake in Arcturus Therapeutics by 6.9% in the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after acquiring an additional 136,074 shares during the period. Millennium Management LLC increased its position in Arcturus Therapeutics by 250.1% during the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after purchasing an additional 396,505 shares during the period. Geode Capital Management LLC increased its holdings in Arcturus Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after buying an additional 5,789 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Arcturus Therapeutics by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock worth $4,587,000 after buying an additional 3,224 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.